2 reports of this reaction
1.6% of all DIPHENHYDRAMINE HCL, ZINC ACETATE reports
#15 most reported adverse reaction
EPISTAXIS is the #15 most commonly reported adverse reaction for DIPHENHYDRAMINE HCL, ZINC ACETATE, manufactured by Bionpharma Inc.. There are 2 FDA adverse event reports linking DIPHENHYDRAMINE HCL, ZINC ACETATE to EPISTAXIS. This represents approximately 1.6% of all 124 adverse event reports for this drug.
Patients taking DIPHENHYDRAMINE HCL, ZINC ACETATE who experience epistaxis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EPISTAXIS is a less commonly reported adverse event for DIPHENHYDRAMINE HCL, ZINC ACETATE, but still significant enough to appear in the safety profile.
In addition to epistaxis, the following adverse reactions have been reported for DIPHENHYDRAMINE HCL, ZINC ACETATE:
The following drugs have also been linked to epistaxis in FDA adverse event reports:
EPISTAXIS has been reported as an adverse event in 2 FDA reports for DIPHENHYDRAMINE HCL, ZINC ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EPISTAXIS accounts for approximately 1.6% of all adverse event reports for DIPHENHYDRAMINE HCL, ZINC ACETATE, making it a notable side effect.
If you experience epistaxis while taking DIPHENHYDRAMINE HCL, ZINC ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.